mutLBSgeneDB |
Gene summary for SPG20 |
![]() |
Basic gene Info. | Gene symbol | SPG20 |
Gene name | spastic paraplegia 20 (Troyer syndrome) | |
Synonyms | SPARTIN|TAHCCP1 | |
Cytomap | UCSC genome browser: 13q13.3 | |
Type of gene | protein-coding | |
RefGenes | NM_001142294.1, NM_001142295.1,NM_001142296.1,NM_015087.4, | |
Description | spartintrans-activated by hepatitis C virus core protein 1 | |
Modification date | 20141219 | |
dbXrefs | MIM : 607111 | |
HGNC : HGNC | ||
Ensembl : ENSG00000133104 | ||
HPRD : 06170 | ||
Vega : OTTHUMG00000016730 | ||
Protein | UniProt: Q8N0X7 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_SPG20 | |
BioGPS: 23111 | ||
Pathway | NCI Pathway Interaction Database: SPG20 | |
KEGG: SPG20 | ||
REACTOME: SPG20 | ||
Pathway Commons: SPG20 | ||
Context | iHOP: SPG20 | |
ligand binding site mutation search in PubMed: SPG20 | ||
UCL Cancer Institute: SPG20 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for SPG20 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | R91 | R91M | LUAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for SPG20 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R91 | R91M | -1.061003 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for SPG20 |
![]() |
![]() |
Top |
Top |
Phenotype information for SPG20 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0393559 | Spastic paraplegia 20, autosomal recessive | 10 | Biomarker, GeneticVariation |
umls:C0279628 | Adenocarcinoma Of Esophagus | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for SPG20 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (ASP,ILE,ASP,PHE,ASP,ASP,LEU,SER,ARG,ARG,PHE,GLU,GLU,LEU,LYS,LYS) | 4u7i | A | R91 |
Top |
Conservation information for LBS of SPG20 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |